Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
To evaluate the efficacy and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma
Epistemonikos ID: e0ae771d69bababaf2eff2cd4af35744b475a571
First added on: May 13, 2024